Pruritus Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
Verified date | May 2021 |
Source | Vyne Therapeutics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
Status | Completed |
Enrollment | 285 |
Est. completion date | February 14, 2020 |
Est. primary completion date | January 14, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria (Subjects must meet the following criteria to be randomized into the study: 1. Male or female, age 18 years or older at consent. 2. Prurigo nodularis (PN), with at least ten nodules on at least two different body surface areas. 3. Idiopathic PN, or an identified pruritic condition associated with the PN with persistent pruritus despite at least 6 weeks of optimized and stable treatment of the underlying condition. 4. The worst pruritus is identified as within the areas of the PN lesions, with a Worst-Itch Numeric Rating Scale (WI-NRS) score in the 24-hour period prior to the Screening visit, and average weekly WI-NRS score in each of the 2 weeks prior to Baseline visit indicating an appropriate pruritus level for the study. 5. Female subjects of childbearing potential must be willing to practice highly effective contraception until 5 weeks after last dose of study drug. 6. Willing and able to complete daily eDiary entries within a consistent timeframe for the duration of the study. 7. Willing and able to comply with study visits and study related requirements including providing written informed consent. Exclusion Criteria (Subjects who meet any of the following criteria are not eligible for participation in the study): 1. Prior treatment with serlopitant. 2. Active pruritic skin disease, other than PN, within 6 months (with the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, which have been resolved for longer than 4 weeks). 3. Treatment with any of the following therapies within 4 weeks. 1. Other neurokinin-1 receptor antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 2. Systemic or topical immunosuppressive/immunomodulatory therapies. 3. Systemic therapies with recognized anti-pruritic properties. 4. Strong cytochrome-P 3A4 inhibitors. 5. Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning or sunburn. 4. Treatment with topical anti-pruritic therapies within 2 weeks. 5. Treatment with biologic therapies within 8 weeks or 5 half-lives, whichever is longer. 6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational biologic therapies) or 5 half-lives, whichever is longer. 7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate aminotransferase > 2.5 times the upper limit of normal during screening. 8. Untreated or inadequately treated thyroid adrenal, or pituitary nodules or disease, or history of thyroid malignancy. 9. Malignancy within 5 years prior to enrollment (exception for non-melanoma cutaneous malignancies). 10. Relevant major psychiatric diagnosis in the past 3 years, such as major depressive disorder, bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use disorder. 11. Documented history of parasitic infection, including skin parasites such as scabies, within 8 weeks. 12. Any medical condition or disability that could interfere with the assessment of safety or efficacy in this study or compromise the safety of the subject. 13. History of hypersensitivity to serlopitant or any of its components. 14. Currently pregnant or breastfeeding or planning to become pregnant during the study. 15. Planned or anticipated major surgical procedure or other activity that would interfere with the subject's ability to comply with protocol-mandated assessments during participation in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Study Site 506 | Ann Arbor | Michigan |
United States | Study Site 365 | Austin | Texas |
United States | Study Site 501 | Aventura | Florida |
United States | Study Site 520 | Bellaire | Texas |
United States | Study Site 516 | Bexley | Ohio |
United States | Study Site 504 | Birmingham | Alabama |
United States | Study Site 379 | Boston | Massachusetts |
United States | Study Site 507 | Brooklyn | New York |
United States | Study Site 508 | Buffalo | New York |
United States | Study Site 509 | Cleveland | Ohio |
United States | Study Site 210 | Coral Gables | Florida |
United States | Study Site 502 | Dallas | Texas |
United States | Study Site 515 | Detroit | Michigan |
United States | Study Site 524 | Dublin | Ohio |
United States | Study Site 201 | East Windsor | New Jersey |
United States | Study Site 534 | Fort Lauderdale | Florida |
United States | Study Site 204 | Fremont | California |
United States | Study Site 525 | Glenn Dale | Maryland |
United States | Study Site 526 | Henderson | Nevada |
United States | Study Site 341 | High Point | North Carolina |
United States | Study Site 224 | Houston | Texas |
United States | Study Site 345 | Johnston | Rhode Island |
United States | Study Site 511 | Knoxville | Tennessee |
United States | Study Site 228 | Louisville | Kentucky |
United States | Study Site 530 | Miami | Florida |
United States | Study Site 531 | Miami | Florida |
United States | Study Site 532 | Morgantown | West Virginia |
United States | Study Site 805 | Nashville | Tennessee |
United States | Study Site 527 | New Orleans | Louisiana |
United States | Study Site 500 | New York | New York |
United States | Study Site 517 | New York | New York |
United States | Study Site 510 | Newnan | Georgia |
United States | Study Site 383 | North Hollywood | California |
United States | Study Site 222 | North Miami Beach | Florida |
United States | Study Site 227 | Omaha | Nebraska |
United States | Study Site 359 | Pflugerville | Texas |
United States | Study Site 523 | Philadelphia | Pennsylvania |
United States | Study Site 522 | Pittsburgh | Pennsylvania |
United States | Study Site 533 | Rogers | Arkansas |
United States | Study Site 371 | Saint Joseph | Missouri |
United States | Study Site 528 | Saint Louis | Missouri |
United States | Study Site 361 | San Antonio | Texas |
United States | Study Site 356 | San Diego | California |
United States | Study Site 514 | Santa Ana | California |
United States | Study Site 388 | Skokie | Illinois |
United States | Study Site 806 | Spokane | Washington |
United States | Study Site 112 | Tulsa | Oklahoma |
United States | Study Site 529 | Verona | New Jersey |
United States | Study Site 226 | Webster | Texas |
Lead Sponsor | Collaborator |
---|---|
Vyne Therapeutics Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 | During the study, Worst Itch Numeric Rating Scale (WI-NRS) assessments were reported by the subject via eDiary once daily from screening/mid-screening visit through the follow-up visit. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects were asked to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable); higher scores indicated greater itch intensity. Subjects were considered responders if they had at least a 4-point reduction from baseline in weekly average WI-NRS at Week 10. | At Week 10 | |
Secondary | Percent of Subjects With WI-NRS 4-point Responder at Week 4 | During the study, WI-NRS assessments were reported by the subject via eDiary once daily from screening/mid-screening visit through the follow-up visit. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects were asked to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable); higher scores indicated greater itch intensity. | At Week 4 | |
Secondary | Percent of Subjects With WI-NRS 4-point Responder at Week 2 | During the study, WI-NRS assessments were reported by the subject via eDiary once daily from screening/mid-screening visit through the follow-up visit. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects were asked to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable); higher scores indicated greater itch intensity. | At Week 2 | |
Secondary | Change From Baseline in WI-NRS at Weeks 2, 4, 6, and 10 | During the study, WI-NRS assessments were reported by the subject via eDiary once daily from screening/mid-screening visit through the follow-up visit. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects were asked to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable); higher scores indicated greater itch intensity. | At Weeks 2, 4, 6, and 10 | |
Secondary | Percent of Subjects With WI-NRS 3-point Responder at Weeks 2, 4, and 10 | During the study, WI-NRS assessments were reported by the subject via eDiary once daily from screening/mid-screening visit through the follow-up visit. The Itch NRS is a validated, self-reported, instrument for measurement of itch intensity and subjects were asked to rate the intensity of their itch on an 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable); higher scores indicated greater itch intensity. For the 3-point responder rate, subjects were considered responders if they had at least a 3-point reduction between baseline and the corresponding week. | At Weeks 2, 4, and 10 | |
Secondary | Change From Baseline in Investigator's Global Assessment of Prurigo Nodularis Activity (IGA PN-A) to Weeks 2, 4, and 10 | The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given time point, as determined by the investigator. It consists of a 5-point scale ranging from 0 (clear) to 4 (severe). Higher scores indicate severe prurigo nodularis. | At Weeks 2, 4, and 10 | |
Secondary | Change From Baseline in Investigator's Global Assessment of PN Stage (IGA PN-S) to Weeks 2, 4, and 10 | The IGA PN-S is an instrument used to assess the overall number and thickness of PN lesions at a given time point, as determined by the investigator. It consists of a 5-point scale ranging from 0 (clear) to 4 (severe). Higher scores indicate severe prurigo nodularis. | At Weeks 2, 4, and 10 | |
Secondary | Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 10 | Dermatology Life Quality Index (DLQI) is a dermatology specific quality of life (QoL) instrument designed to assess the impact of the skin disease on a subject's QoL over the prior week. It is a ten item questionnaire that assesses overall QoL and six aspects that may affect QoL (symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment). The DLQI questions are rated by the subject as 0 (not at all) to 3 (very much). Scores range from 0 to 30 with higher scores indicating poor QoL. | At Week 10 | |
Secondary | Change From Baseline in DLQI Question 1 to Week 10 | DLQI is a dermatology specific QoL instrument designed to assess the impact of the skin disease on a subject's QoL over the prior week. It is a ten item questionnaire that assesses overall QoL and six aspects that may affect QoL (symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment) The DLQI question 1 is to measure how itchy, sore, painful or stinging the subject's skin had been. It is rated by the subject as 0 (not at all) to 3 (very much). Scores range from 0 to 30 with higher scores indicating poor QoL. | At Week 10 | |
Secondary | Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events (SAEs) | Adverse events (AEs) and serious adverse events (SAEs) were recorded from the first study drug administration through the follow-up visit. Severity of all AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03. During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention were collected. | 35 days (+3 days) after Week 10 or Early Treatment Discontinuation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Terminated |
NCT01825655 -
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
|
Phase 4 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT01236859 -
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus
|
N/A | |
Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 |